


PHARMACEUTICAL 2020



NightHawk Biosciences Inc. Rank 234 of 358





PHARMACEUTICAL 2020



NightHawk Biosciences Inc. Rank 234 of 358

The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 45% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 13%, being 24% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	15,209
Cost of Goods Sold	0
Intangible Assets	7,366
Liabilities, Current	8,435
Liabilities, Non-Current	1,720
Other Assets	2,822
Other Compr. Net Income	376
Other Expenses	1,395
Other Liabilities	2,644
Other Net Income	406
Other Revenues	3,049
Property and Equipment	559
Research and Development	13,014
Selling, General and Administrative Expense	9,431

Output Variable	Value in 1000 USD
Assets	25,957
Liabilities	12,799
Expenses	23,840
Revenues	3,049
Stockholders Equity	13,158
Net Income	-20,385
Comprehensive Net Income	-20,197
Economic Capital Ratio	13%

